fda compounding semaglutide warning 2025 october National Hispanic Medical Association | After compounded GLP-1 drugs were banned, counterfeit versions continued to circulate — and still do today. Understanding the risks and FDA Issues Warning: Compounding Certain

While there are limited studies specifically examining Wegovy in people with hypothyroidism, the medication wasnt contraindicated for patients with controlled hypothyroidism in the STEP clinical trials

Some weight regain is possible during a month off tirzepatide as the medication's appetite-suppressing effects diminish, though substantial regain typically occurs over longer periods depending on diet, activity level, and individual metabolism

A 2022 study published in the Journal of Pharmaceutical Sciences found that reduced L-glutathione stored at room temperature (25C) lost 40% potency within 90 days

One study has found that the primary reason patients drop out of GLP-1 medication programs, is due to the side effects caused by the drugs

The results were consistent with the overall SELECT trial findings and showed a numerically larger risk reduction in the perimenopausal women (42% lower risk compared to placebo) compared to the postmenopausal women (13% lower risk compared to placebo), although the difference between the groups was not statistically significant

Risk factors for semaglutide-induced gastroparesis Published case reports highlight several patterns